Showing posts with label Vaccines Market. Show all posts
Showing posts with label Vaccines Market. Show all posts

Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry now available at ReportsnReports


Original Source : Vaccines Industry



Vaccines have been one of the faster growing areas of the pharmaceutical industry, and during a troubling series of years, they have been the superstars of many companies' portfolios. They've also attracted the attention of insurance companies, retail outlets and the media. The global market for vaccines experienced strong growth through 2009 and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions.
Kalorama Information has been closely following vaccine markets and since 2006 has instituted a yearly market research report schedule to keep up with fast-moving developments. Our latest comprehensive update, Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, examines the market for vaccines used in humans for various disease. This state-of-the-industry report is a must-have for any executive who wants to stay on top of a rapidly changing market and see what’s expected down the road. You can count on the objectivity and accuracy of our numbers and analysis—whether you're preparing a strategic presentation, benchmarking your company's performance against the competition, preparing a new product launch or seeking out an acquisition or a new partnership.
The report covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable.
Included in this report are current market size and forecast for the following vaccines:
  • Combinations
  • Hepatitis
  • HIB
  • MMR
  • Pneumococcal
  • Poliovirus
  • Varicella
  • Other Pediatric
  • Cervical Cancer
  • Hepatitis
  • Influenza
  • Pneumococcal
  • Travel; DT; Misc.
Important trends such as vaccine safety, vaccine shortages, preventing pandemics, vaccines and bioterrorism, DNA vaccination, innovations in vaccine delivery systems and innovations in vaccine Production are covered in the report. In addition, the reort profiles key competitors in the vaccine industry. Companies profiled in the report include:
  • AlphaVax, Inc.
  • Bavarian Nordic A/S
  • Baxter Healthcare
  • Bharat Biotech
  • Celldex Therapeutics
  • Crucell
  • Emergent biosolutions
  • GlaxoSmithKline
  • Medimmune
  • Merck & Co. Inc
  • Nabi Biopharmaceuticals
  • Novartis
  • Pfizer
  • Sanofi Pasteur
Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the historic 2005 to 2009 period and forecasts are provided through 2014. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.

Table Of Contents

CHAPTER ONE: EXECUTIVE SUMMARY
The Global Vaccine Industry
Scope and Methodology
Overview
Pediatric Preventative Vaccines
The Market
Adult Preventative Vaccines
The Market
Total Market
Issues and Trends

CHAPTER TWO: INTRODUCTION TO VACCINES
A Brief History: The Development of Vaccines
The Immune Response
Mechanism of Action
Types of Vaccines
Attenuated (Weakened) Live Viruses
Killed (Inactivated) Viruses
Toxoid Vaccines
Genetically Engineered/Modified Vaccines
Subunit Vaccines
Conjugate Vaccines
DNA Vaccination
Vaccine Approval Process
CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES
Introduction
Childhood Immunization in the United States
Childhood Immunization Rates
Challenges to the Vaccine Delivery System
The Effect of U.S. Health Care Reform
Recommended Childhood Immunization Schedule
State Immunization Recommendations
United Nations Initiatives
Pediatric Vaccine Products
BCG
Diphtheria, Tetanus, Pertussis, Hepatitis B and Polio
Diphtheria
Pertussis
Tetanus
Hepatitis B
Poliomyelitis
Haemophilus Influenzae Type B
Hepatitis A
Measles, Mumps and Rubella
Measles
Mumps
Rubella
Meningococcal Disease
Pneumococcal Conjugate
Rotavirus
Varicella
Pediatric Vaccines in Development
Cost of Vaccines in the United States The World Market for Pediatric Preventive Vaccines
Total Market Size and Forecast
Hepatitis Vaccine Market
Market Analysis
Leading Products and Competitors
Haemophilus Influenzae Type B Vaccine Market
Market Analysis
Leading Products and Competitors
Measles, Mumps and Rubella Vaccines
Market Analysis
Combination Vaccines Market
Market Analysis
Leading Products and Competitors
Pneumococcal Vaccine
Leading Products and Competitors
Poliovirus Vaccine
Market Analysi
Leading Products and Competitors
Varicella Vaccine
Market Analysis
Leading Products and Competitors
Other Vaccines Market
Market Analysis
Leading Products and Competitors

CHAPTER FOUR: ADULT PREVENTIVE VACCINES
Introduction
Adult Vaccine-Preventable Diseases: Facts and Figures
Global Influenza Surveillance Program
Recommendations for Adult Immunizations
WHO International Health Regulations
Adult Vaccine Products
BCG
Cervical Cancer
Cholera
Diphtheria-Tetanus
Hepatitis
Hepatitis A
Hepatitis B
Influenza
Japanese Encephalitis
Pneumococcal Disease
Rabies
Shingles
Typhoid Fever
Yellow Fever
Adult Vaccines in Development
Total Market Size and Forecast
Cervical Cancer Market
Market Analysis
Leading Products and Competitors
Hepatitis Market
Market Analysis
Leading Products and Competitors
Influenza Vaccine Market
Market Analysis
Leading Products and Competitors
Market Analysis
Leading Products and Competitors
Travel, DT, and Miscellaneous Vaccine Market
Market Analysis
Leading Products and Competitors
CHAPTER FIVE: VACCINES MARKET SUMMARY
Trends Driving the Vaccines Market
Market Size and Forecast
Vaccine Sales by Region
Vaccine Market Competitors
Pediatric Vaccines
Major Manufacturer’s Market Share
Adult Vaccines
Major Manufacturer’s Market Share

CHAPTER SIX: ISSUES AND TRENDS
Vaccine Safety
Refusal to Immunize
Obesity
Post-Licensure Surveillance
Vaccine Adverse Event Reporting System
The Vaccine Safety Datalink Project
Phase IV studies
The Vaccine Injury Compensation Program
Countermeasures Injury Compensation Program
World Health Organization
Other Initiatives
The Future of Vaccine Safety
Vaccine Shortages
Preventing Shortages in the Developed Countries
Financial incentives
Equitable pricing
Vaccine stockpiles
Preventing Shortages in Developing Nations
Vaccine bonds
Preventing Pandemics
U.S. National Vaccine Plan
Vaccines and Bioterrorism
Overview
Project Bioshield Act
National Bio and Agro-Defense Facility
Vaccine Treatment and Evaluation Units
Anthrax
Smallpox
Tularemia
Viral Hemorrhagic Fevers
DNA Vaccination
Innovations in Vaccine Delivery Systems
Edible Vaccines
Mucosal Delivery
Intranasal Delivery
Vaccine Patches
Vaccine Chips
Innovations in Vaccine Production
Tobacco Plants
Insects
Nanoparticle Systems

CHAPTER SEVEN: COMPANY PROFILES
AlphaVax, Inc.
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Bavarian Nordic A/S
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Baxter Healthcare
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Bharat Biotech
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Celldex Therapeutics
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Crucell
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Emergent Biosolutions
History and Lines of Business
Strategic Acquisition and Alliance
Vaccine Products
Financial
GlaxoSmithKline
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Medimmune
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Merck & Co. Inc
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Nabi Biopharmaceuticals
History and Lines of Business
Strategic Alliance
Vaccine Products
Financial Information
Novartis
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Pfizer
History and Lines of Business
Strategic alliances
Vaccine Products
Financial Information
Sanofi Pasteur
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information

ABBREVIATIONS
Browse all : Medical Devices
Browse all : Kalorama Information
Browse all : Newly Published

Related Reports :

About Us:
ReportsnReports  is comprising of an online library of 50,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites.
Our client list boasts of almost all well-known publishers of such reports across the globe. We, as a third party reseller of market research reports employ number of marketing tools such as press releases, email-marketing and effective search engine optimization technique to drive revenues for our clients.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , |

ReportsandReports - Innovations and Opportunities in Therapeutic Vaccines: Technology platforms, key players, and early pipeline candidates



Therapeutic vaccines promise a new wave of highly potent and highly specific therapeutic agents designed to work in harmony with patients’ own immune systems. Recent advances in the understanding of the human immune system and in technical capabilities have allowed vaccines to move beyond pre-emptive (prophylactic) immunization and into treatment of established diseases. In April 2010, Dendreon’s Provenge became the first ever cancer vaccine to be approved by the US Food and Drug Administration (FDA), overcoming skepticism in the investment community and paving the way for a new generation of biological therapies.

This report explains what therapeutic vaccines are, how they work, and why drug developers around the world are using this approach to address everything from allergies to literally every kind of cancer. More than 70 new proprietary technologies are named and explained, with details of licensing deals and intellectual property positions.

The newest wave of drug candidates based on these technologies can be seen in more than 130 early pipeline candidates, each based on a commercial company or research institute known to have carried out preclinical and/or Phase I trials of at least one therapeutic vaccine candidate in the past year. By way of background, later stage candidates being developed by the same companies are also discussed. In total, more than 270 therapeutic vaccine candidates are identified in this report. Finally, prospects and challenges for the future of this field are discussed, with opinions from around 20 prominent industry leaders and academic researchers.

Key features of this report
  • Beginners guide’ to vaccines and the human immune system, illustrated with original full-color diagrams, to show the potential challenges and benefits of therapeutic vaccination.
  • More than 70 descriptions of proprietary technologies currently in use around the world to design, produce and administer therapeutic vaccines.
  • A comprehensive guide to companies around the world that are currently developing brand new therapeutic vaccines (i.e. candidates in preclinical or Phase I clinical trials).
  • Details of more than 270 specific vaccine candidates, in development by around 120 different companies and research institutes.
  • Expert opinions on the opportunities, challenges and future trends in the therapeutic vaccine field from around 20 industry leaders and academic researchers, over a dozen of whom were contacted directly and interviewed for this report.
Scope of this report
  • Understand the basic qualities of vaccines and how these qualities translate into unique medical and commercial features for therapeutic candidates.
  • Appreciate the challenges and risks of therapeutic vaccines, as well as their promise.
  • Assess emerging technologies for possible investment or in-licensing.
  • Identify which companies are involved in this field, and what they are doing.
  • Predict the kinds of drug that may reach the market over the next ten years.
  • Tailor your own company’s strategies to take advantage of upcoming opportunities, such as the validation of new technologies in human patients.
Key Market Issues
  • Therapeutic vaccines hold the potential to address diseases with a high unmet need for effective, i.e. markets that are currently under-penetrated.
  • Much like monoclonal antibodies, the inherent specificity of vaccines may shorten drug development times and increase rates of success in preclinical and clinical trials, now that the intricacies of the human immune system are better understood.
  • The recent US approval of Dendreon’s personalized cancer vaccine Provenge has established a precedent and a recognized path to regulatory approval for therapeutic vaccines.
  • Newer technologies target the same basic immune system processes as Provenge, but may result in cheaper and more broadly applicable therapies.
Key findings from this report
  • New technical capabilities and better understanding of the human immune system has recently allowed vaccination approaches to be applied to therapeutic settings as well as prophylaxis.
  • Demand for therapeutic vaccines is high, and profits from launched drugs are expected to achieve ‘blockbuster’ levels (billions of US dollars per annum).
  • Treatment of established diseases requires different immune reactions to protective (prophylactic) immunity, to overcome existing disease burdens and immuno-avoidance mechanisms, so immune responses must be ‘modulated’ rather than just stimulated.
  • Many new candidates use multiple ‘antigen’ targets, or multiple variants of a single target, to address heterogeneity in both disease targets and patients’ immune systems.
  • Vaccine approaches can also be used to inhibit immune responses to specific ‘antigens’, making them useful for treating allergies, autoimmune diseases and transplant rejection.
  • Various vectors (carriers) and adjuvants (immunostimulators), each with their own benefits and drawbacks, are being used to enhance the delivery of vaccine antigens to target immune cells and to modulate the strength and type of immune responses that result.
Key questions answered
  • What are therapeutic vaccines, and what can they do?
  • Why are so many companies and research institutes working on therapeutic vaccines?
  • Which companies are currently working to validate and develop the latest generation of drug candidates based on therapeutic vaccines?
  • What technological and regulatory challenges face these companies in developing such candidates and bringing them to market?
  • What technologies are being used to design, produce and administer these drug candidates?
  • Who developed these technologies, and who is using them right now?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , |